Crossmark

Ultrasound as a potential tool for the assessment of interstitial lung disease in rheumatic patients. Where are we now?

Published Online: 2019-07-02

Published Print: 2019-10

Authors

Gutierrez, Marwin https://orcid.org/0000-0002-7995-1110
Tardella, Marika https://orcid.org/0000-0003-4764-7197
Rodriguez, Luis https://orcid.org/0000-0001-9511-8527
Mendoza, Jaime https://orcid.org/0000-0002-7432-3756
Clavijo-Cornejo, Denise https://orcid.org/0000-0002-6399-9865
García, Antonio https://orcid.org/0000-0002-7442-8486
Bertolazzi, Chiara https://orcid.org/0000-0002-4665-6596
License Information

Text and Data Mining valid from 2019-07-02

Version of Record valid from 2019-07-02
More Information

Article History

Received: 4 April 2019

Accepted: 18 June 2019

First Online: 2 July 2019

Compliance with ethical standards

:

: The authors would like to make the following statements with regard to their conflicts of interest/financial disclosures: MG has attended advisory board meetings and scientific consultancies and has obtained speaking fees for: AbbVie, Novartis, UCB, Esaote SpA, Janssen, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Sanofi Aventis. MT, LR, JM, DC-C, AG, CB declare that they have no competing interests.

: This article does not contain any studies with human participants or animals performed by any of the authors.

Document is current